This study looks at how well BGB-16673 works compared to other treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Participants in this trial will have already received two types of treatments for their cancer. The main goal is to see how long people can live without their condition getting worse after taking BGB-16673 versus other treatment options.
This is a Phase 3 trial, which means it is looking at how well the treatments work and how safe they are. The trial plans to include about 250 participants and is FDA-regulated.
Who can join
Adults aged 18 and older can join if they have a confirmed diagnosis of CLL or SLL and have previously received both a BTK inhibitor and a BCL2 inhibitor. Participants must also have measurable disease and good liver and blood clotting function. Those with certain other conditions or recent treatments may not be eligible. The trial team will confirm if you qualify.
Conditions
CLL, Chronic Lymphocytic Leukemia
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly assigned to one of two groups. One group will receive BGB-16673, taken once daily. The other group will receive a treatment chosen by the investigator, which could include medications like idelalisib plus rituximab, bendamustine plus rituximab, or venetoclax plus rituximab. Everyone will be monitored to see how well the treatments work.
Where
This trial is enrolling at 21 locations. Recruiting sites are listed first.
Elected to the National Academy of Medicine. Treats leukemia and myelodysplastic syndrome. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.
Professor and transplant specialist, UC Davis. Treats leukemia, lymphoma and multiple myeloma. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.